Evidence map›Paper›PMID 37358519›Full record

ReviewComprehensive Physiology2023

Extracellular Vesicles in Hepatobiliary Health and Disease.

Gopanandan Parthasarathy, Petra Hirsova, Enis Kostallari, Guneet S Sidhu, Samar H Ibrahim, Harmeet Malhi

Open access · greenAbstract readReview
In one paragraph

Review in Comprehensive Physiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Gopanandan ParthasarathyDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Petra HirsovaDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Enis KostallariDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Guneet S SidhuDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Samar H IbrahimDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Harmeet MalhiDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Mayo Clinic · USWinnMed · US

Funding

PILOT AND FEASIBILTY PROGRAMP30DK084567 · NIDDK · MAYO CLINIC ROCHESTER · PI Samar Ibrahim · 2009 to 2026
$22.2M
TREAT-MayoU01AA021788 · NIAAA · MAYO CLINIC ROCHESTER · PI MALHI, HARMEET, SHAH, VIJAY H. · 2012 to 2022
$4.7M
Pathobiology of Liver InjuryR01DK111378 · NIDDK · MAYO CLINIC ROCHESTER · PI MALHI, HARMEET · 2016 to 2025
$3.9M
Lipotoxicity and Liver InflammationR01DK122948 · NIDDK · MAYO CLINIC ROCHESTER · PI Samar Ibrahim · 2020 to 2026
$3.1M
Pathobiology of Nonalcoholic SteatohepatitisR01DK130884 · NIDDK · MAYO CLINIC ROCHESTER · PI Petra Hirsova · 2021 to 2026
$2.5M
NIAAA NIH HHS U01 AA021788NIDDK NIH HHS P30 DK084567NIDDK NIH HHS R01 DK111378NIDDK NIH HHS R01 DK122948NIDDK NIH HHS R01 DK130884
6 · The paper itself

Abstract

Extracellular vesicles (EVs) are membrane-bound nanoparticles released by cells and are an important means of intercellular communication in physiological and pathological states. We provide an overview of recent advances in the understanding of EV biogenesis, cargo selection, recipient cell effects, and key considerations in isolation and characterization techniques. Studies on the physiological role of EVs have relied on cell-based model systems due to technical limitations of studying endogenous nanoparticles in vivo . Several recent studies have elucidated the mechanistic role of EVs in liver diseases, including nonalcoholic fatty liver disease, viral hepatitis, cholestatic liver disease, alcohol-associated liver disease, acute liver injury, and liver cancers. Employing disease models and human samples, the biogenesis of lipotoxic EVs downstream of endoplasmic reticulum stress and microvesicles via intracellular activation stress signaling are discussed in detail. The diverse cargoes of EVs including proteins, lipids, and nucleic acids can be enriched in a disease-specific manner. By carrying diverse cargo, EVs can directly confer pathogenic potential, for example, recruitment and activation of monocyte-derived macrophages in NASH and tumorigenicity and chemoresistance in hepatocellular carcinoma. We discuss the pathogenic role of EVs cargoes and the signaling pathways activated by EVs in recipient cells. We review the literature that EVs can serve as biomarkers in hepatobiliary diseases. Further, we describe novel approaches to engineer EVs to deliver regulatory signals to specific cell types, and thus use them as therapeutic shuttles in liver diseases. Lastly, we identify key lacunae and future directions in this promising field of discovery and development. © 2023 American Physiological Society. Compr Physiol 13:4631-4658, 2023.

Indexed as

Extracellular VesiclesNon-alcoholic Fatty Liver DiseaseBiological TransportHumansModels, Biological

Identifiers

PMID37358519
PMCPMC10798368
OpenAlexW4382011612

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.